Mitoxantrone-induced cardiotoxicity

Journal of Oncology Pharmacy Practice

Volumn 7, Issue 1, 2001, Pages 47-48

  Darko, William ^a   Smith, Adrienne L ^a   King, Evelyn L ^a   Grethlein, Sara J ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Cardiotoxicity; Mitoxantrone

Indexed keywords

ACICLOVIR; ALLOPURINOL; ANTHRACYCLINE; CIPROFLOXACIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANISETRON; IDARUBICIN; LORAZEPAM; MAGNESIUM SULFATE; MITOXANTRONE; POTASSIUM CHLORIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CASE REPORT; DOSE RESPONSE; DRUG USE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; PATIENT MONITORING; PRIORITY JOURNAL; QT INTERVAL; RISK FACTOR; SINUS BRADYCARDIA; SYMPTOMATOLOGY; THORAX PAIN;

EID: 0035724785     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155201jp079cr     Document Type: Article

References (18)

1. Anthracycline-induced cardiotoxicity
2. Cardiotoxicity in patients treated with mitoxantrone on Southwest Oncology Group: Phase II protocols
3. Cardiac events in phase II trials with mitoxantrone in acute myelocytic leukemia cells in culture
4. Mitoxantrone cardiotoxicity: Results from southeastern cancer study group
5. Mitoxantrone: A new anticancer drug with significant clinical activity
6. Comment on mitoxantrone
7. Mitoxantrone
8. Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography
9. Mitoxantrone: An overview of safety and toxicity
10. Bradycardia due to mitoxantrone exacerbated by previous anthracycline therapy
11. Bradycardia due to anthracyclines
12. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer
13. Comparison study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxic animal model
14. Mitoxantrone-induced bradycardia
15. Clinical safety and tolerance of mitoxantrone
16. Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies
17. Mitoxantrone for the treatment of advance breast cancer: Single-agent therapy in previously untreated patients
18. Sinus bradycardia due to mitoxantrone